TickerFacts.

Iovance Biotherapeutics, Inc. (IOVA): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$90.32M
Year ended 2025-12-31
2023-12-31: $156.0K2024-12-31: $70.82M2025-12-31: $90.32M$90.32M
2023-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$90.32M+27.5%2026-02-24, From 2025-01-01
2024-12-31$70.82Mn/m2026-02-24, From 2024-01-01
2023-12-31$156.0Kn/a2026-02-24, From 2023-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$90.32M+27.5%
Vericel Corp (VCEL)2025-12-31$205.60M+19.5%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$205.62M+92.4%
Twist Bioscience Corp (TWST)2025-09-30$191.00M+43.2%
REGENXBIO Inc. (RGNX)2024-12-31$49.76M-6.2%
ADMA Biologics, Inc. (ADMA)2025-12-31$292.76M+33.3%
Repligen Corp (RGEN)2025-12-31$386.25M+40.6%
Autolus Therapeutics plc (AUTL)2025-12-31-$20.98Mn/m
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$3.73M-72.6%

Compare IOVA, VCEL, ADPT, TWST side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗